Vir Corp (VIR) Price-to-Projected Revenue Ratio

Brandmark of Vir Biotechnology, Inc. (VIR)

The success of Vir Biotechnology, Inc. (VIR) depends on the commercial implementation of hepatitis antibodies in collaboration with partners. The forward P/S based on forecasts allows for an assessment of market expectations, while 5.60 expresses the current value of this metric. The business is not subject to economic cycles thanks to substantial cash reserves. The company's revenues are based on grants, royalties, and the commercialization of its own immunological developments.

VIR (vir.bio) Forward Price to Sales history from 07/04/2022 to 11/14/2026

Analytical breakdowns for Vir Biotechnology, Inc.

- current price and projected stock value:
Stock Price Vir Biotechnology|VIR - Analyst Median Target
- market capitalization details:
Market Value Vir Corp|VIR - Value Adjusted for Debt and Cash
- book value of equity indicators:
Accounting Value per Share Vir Biotechnology|VIR - Accounting Value of Company|Market Capitalization to Book Value Ratio vir.bio|VIR - Aggregate Company Assets
- debt and solvency information:
Total Debt to Capital Vir Biotechnology, Inc.|VIR - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Vir Biotechnology, Inc.|VIR - Company Cumulative Debt|Debt to Book Value Vir Corp|VIR - Amount of Long-Term Liabilities|Company Short-Term Debts Vir Biotechnology|Quick Ratio vir.bio
- net income and valuation multiples indicators:
VIR - Net Income|Projected Future Earnings Vir Biotechnology, Inc.|VIR - Company Value to Net Income|Future Price to Earnings Vir Bio|VIR - Growth-Adjusted P/E Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Vir Corp|VIR - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Vir Biotechnology|VIR - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last twelve months vir.bio|VIR - Earnings per share growth rate in current year|Earnings growth forecast for next year Vir Biotechnology, Inc.
- company sales and revenue statistics:
VIR - Company Total Sales Volume|Company Future Sales Volume Vir Biotechnology|VIR - Price to Sales|Forward Price-to-Revenue Multiple Vir Corp
Initial company analysis:Vir Biotechnology (VIR)
Product sample of Vir Biotechnology, Inc.

The forward P/S ratio assesses the market value of a business relative to expected revenue, determining the extent of the premium paid for future success. Analyzing the expected P/S value allows for a comparison of current market capitalization against projected sales volumes. This metric is calculated as the ratio of the share price to the predicted revenue per share. For Vir Biotechnology, Inc. (VIR), this indicator remains stable, as massive cash reserves ensure that research remains independent of economic cycles.

Competing companies

Forward P/S Multiple GILD (Gilead Sciences)|Market Cap to Expected Sales Ratio Cidara Therapeutics Corp (CDTX)|NVAX - Price-to-Projected Revenue Ratio|Forward Price to Sales CVAC (CureVac Pharma)|VALN (Valneva SE) - Forward Price-to-Revenue Multiple|siga.com - Forward Price to Sales|EBS (Emergent BioSolutions Inc.) - Forward P/S Multiple|Price-to-Projected Revenue Ratio AVIR|Forward P/S Multiple IVVD|Market Cap to Expected Sales Ratio Enanta Pharmaceuticals, Inc|Price-to-Projected Revenue Ratio Inovio Pharmaceuticals INO|hillevax.com (HLVX) - Market Cap to Future Revenue Ratio|KLRS: Forward Price-to-Revenue Multiple|Dyadic International - Price to Expected Revenue Ratio|NNVC: Forward P/S Multiple|Market Cap to Future Revenue Ratio Talphera Corporation (TLPH)|COCP (Cocrystal Pharma, Inc.) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Traws Therapeutics (TRAW)|Forward P/S Multiple DWTX|QLGN (Qualigen Therapeutics Inc) - Forward Price to Sales|Price-to-Projected Revenue Ratio AlloVir ALVR|VBIV: Market Cap to Projected Revenue|VIRI - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Vaxart, Inc.